This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

CSL - CSL Limited

Jump to new
For all CSL Tragics, the following info may be of use to you.
The first chart below is for CSL ADR on the FWB Exchange, this chart is in EUROS.
The snapshot below that chart explains the RED “K” warnings on the chart.
The Chart below shows what happened overnight on our Friday 27/6/25 after the ASX Closed - it is usually an indication of what we should expect on our next trading day which will be Monday 30/6/25.



Note the other 4 Indicators are all negative, the CCI is really Bad, the DMI is @ Nr 5, and the MFI has been under water for most of the time since late Oct 2024, and the Linear Regression is still in Downtrend.


Now the next snapshot is of our CSL on our ASX.

Note that the indicators are similar to those in the FWB Exchange Chart, except that the DMI is @ Nr 11.

The next Snapshot explains a bit about the DMI & how to read it.


The 64 Dollar Question is, “where to next for our CSL”?
Hmmmmm, it looks obvious to me.
What do you think.
Remember to DYOR.

Note - The CSL IV atm is about $210.49 - To understand the IV it may help if you read the explanations in the Forum "DrBourse FA Help for Beginners".

Cheers.
DrB.
 
I may have to channel my inner Nostradamus & predict the Future as all analyst's think they can do & constantly get it wrong ha ha

I will be Buying Next week!!!!!
 
just Think Dr....If you get it wrong, no one really cares, but if you get it right you can beat your chest & do The Dalio Dance & we all know how many predictions he gets right.
 
Good morning
Published today (11/07/25) via NewCorp Media:


Morgans Financial analyst Derek Jellinek reiterates his Buy rating on CSL while trimming his target price 7.8 per cent to $303.70. He says the share price is “materially undervalued”.

On his estimates, CSL now trades on a an EV/EBIT multiple of of 18.2, more than 25 per cent below its 10-year average of 24.7 times.
“Notably, the market appears to be valuing CSL on less than a single division, with a 10 per cent discount to the core Behring business alone, while effectively assessing zero or negative value to Seqirus and Vifor,” Dr Jellinek says.

“While the threat of US tariffs and risk of drug-pricing reform under the Most Favoured Nation executive order and US policy changes under Health Secretary Robert F. Kennedy Jr. have negatively impacted investor sentiment across the global healthcare sector, we believe CSL’s current trading levels are significantly below fair value, pricing it as less than a single-division company, with the main Behring division alone justifying a higher valuation and no value assigned to either Seqirus or Vifor.”

Have a very nice weekend.

Kind regards
rcw1
 
Hmmmmm. - B careful rcw.
"On his estimates" & "we believe", huh, - even though his estimates & beliefs bear no relationship to any of CSL's Financial (Ratios & MOS), or to any of their TA.
Not a very good advertisement for Morgans Financial, you would have thought they would put more emphasis on FACTS like Ratio's & MOS, but no, they prefer "On his estimates" & "we believe".
Good Luck with that.
DrB

Note: the CSL IV is still abt $210.00 at best.
 
qldfrog said:
Doc is a bull in CSL put options
Click to expand...
I know you are only joking frog, as indicated by your 'wink'.

BUT, just so everyone knows, I have been posting the same very basic statement in various Chat Rooms over the past 30+ years.

"I have only ever traded 'Long', with my own funds, and I have never 'shorted, or used options', trading long has always been the only way for me to trade".

I have always tried to save beginners from loosing their Hard Earned by highlighting Expensive Stocks - and CSL has been at the top of my Expensive List for many years.

My record on calling out the CSL ramping is here for everyone to see.

Cheers..
 
Thank you Dr Bource for your efforts. It's definitely a pool of sharks out there waiting for a free feed of fresh fish.
 
I follow your posts Dr with great interest, and when the news came of tariff for Drugs from Australia, I entered a low ball offer for CSL @$192 before market open;
What is actually stunning is that my broker actually let me do it, and kept it active!
It a word, they do not think it was a typo or a crazy order..whereas believe me, a lot of my low ball orders are usually just bounced back within minutes even when nowhere near as far from the SP as my $192 buy...
Whatever it might mean...
 
Word is out that CSL is looking to consolidate its R&D teams around six sites, including Melbourne, and increasingly rely on external partnerships and potentially acquisitions to fill any gaps. Fuller details are likely to be available when the company releases full-year results on 19 August.

The 2500-strong R&D workforce will be reduced with speculation inside the company that up to one-third of the R&D staff could go. CSL has already shut down its R&D hub for cell and gene therapy in Pasadena, California, with activities shifted to Massachusetts, according to reports in trade press.

“We are streamlining the R&D organisation to foster collaboration, reduce duplication and improve efficiencies, and we are simplifying our operating mode,” a CSL spokesman said.
Click to expand...

“We will increasingly depend on a more optimal mix of internal capabilities and external partnerships to build and deliver our R&D pipeline. This will require a smaller global internal workforce in the future.”
Click to expand...

CSL invested $US1.4 billion ($2.1 billion) in R&D in 2024, bringing the total to $US5.8 billion over the last five years. It typically invests in work that underpins its three main businesses – blood plasma, vaccines and iron deficiency – with a focus on late-stage clinical development programs.
 
When a company cuts back on R&D expenditure its often not a good sign. It means short termism is creeping into the company culture.

If the company really wanted to cut costs fire management employees, admin employees and HR employees (these 3 groupings of employees usually contain the most dead weight, the type of people who spend half of their day on instagram). You shouldn't be cutting R&D employees they are the engine room of growth. Literally firing some of the most important people in the company and keeping the dead weight. Its the equivalent of cutting the flowers and watering the weeds.
 
And with AI tools now suitable, you do not cut r&d but admin accounting hr ( as you keep but do not add to r&d)
 
Looks as though someone found a “Light Switch” in the CSL boardroom.
It’s about 7 years late, and it’s only one of several switches they need to activate.
The best thing they could do, would be to stop feeding so much rubbish to the Brokers of this world.

Bring the SP back to under $150 and they will ALMOST be back to reality.
Give them another 3years or so, and they may get it right.
 
Keep Bagging a Great Australian Company!.....the world will always need blood!

"Mr Market" will determine who is right....the Buyers or the sellers?.....I'm on the side of the Buyers
 
You must log in or register to reply here.

Similar threads

Research Articles
Replies
14
Views
2K
Rypieee
Can you make money investing in watches?
2 3
Replies
58
Views
5K
JohnDe
VGN - Virgin Australia
Replies
10
Views
1K
Dona Ferentes
August 2025 DDD
2 3
Replies
54
Views
7K
ducati916
A Sure Thing?
2
Replies
36
Views
3K
farmerge
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...